



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Yongsheng Li
✉ yongshengli2005@163.com
Yan Li
✉ pipili@sina.com
Houjie Liang
✉ lianghoujie_1259@sina.com

[†]These authors have contributed
equally to this work

RECEIVED 22 October 2025

REVISED 28 October 2025

ACCEPTED 06 November 2025

PUBLISHED 18 November 2025

CITATION

Xiong S, Yang C, Fu K, Liao X, Ding Y, Zhou K,
Zhang L, Teng Y, Wu C, Li Y, Liang H and Li Y
(2025) Correction: Case Report: Curative
effect and mechanism of surufatinib
combined with toripalimab in the
treatment of 1 case of lung large-cell
neuroendocrine carcinoma.
Front. Oncol. 15:1730518.
doi: 10.3389/fonc.2025.1730518

COPYRIGHT

© 2025 Xiong, Yang, Fu, Liao, Ding, Zhou,
Zhang, Teng, Wu, Li, Liang and Li. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](#)
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma

Shuanglong Xiong^{1†}, Chengxiang Yang^{1†}, Kaiwen Fu¹,
Xingyun Liao¹, Yao Ding¹, Kexue Zhou¹, Li Zhang¹, Yan Teng¹,
Chunman Wu², Yongsheng Li^{1*}, Houjie Liang^{3*} and Yan Li^{1*}

¹Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China, ²Nanjing
Geneseeq Technology Inc, Nanjing, China, ³Department of Oncology and Southwest Cancer Centre,
Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China

KEYWORDS

lung large-cell neuroendocrine carcinoma, Surufatinib, toripalimab, immune
microenvironment, TMB

A Correction on

Case Report: Curative effect and mechanism of surufatinib combined with
toripalimab in the treatment of 1 case of lung large-cell neuroendocrine
carcinoma

By Xiong S, Yang C, Fu K, Liao X, Ding Y, Zhou K, Zhang L, Teng Y, Wu C, Li Y, Liang H and Li Y
(2025) *Front. Oncol.* 15:1527719. doi: 10.3389/fonc.2025.1527719

Author “Chunman Wu” was erroneously assigned to affiliation “Chongqing University
Cancer Hospital”. This affiliation has now been removed for author “Chunman Wu”.

Affiliation “Nanjing Geneseeq Technology Inc, Nanjing, China” was omitted for author
“Chunman Wu”. This affiliation has now been added for author “Chunman Wu”.
Shuanglong Xiong^{1†}, Chengxiang Yang^{1†}, Kaiwen Fu¹, Xingyun Liao¹, Yao Ding¹, Kexue
Zhou¹, Li Zhang¹, Yan Teng¹, Chunman Wu², Yongsheng Li^{1*}, Houjie Liang^{3*} and Yan Li^{1*}

¹Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China,
²Nanjing Geneseeq Technology Inc, Nanjing, China, ³Department of Oncology and
Southwest Cancer Centre, Southwest Hospital, Army Medical University (Third Military
Medical University), Chongqing, China.

The **Conflict of interest** statement has been correct to “Author CW was employed by
Nanjing Geneseeq Technology Inc. The remaining authors declare that the research was
conducted in the absence of any commercial or financial relationships that could be
constructed as a potential conflict of interest.”

The funder “1. Beijing Xisike Clinical Oncology Research Foundation (Y-HH202102-0200);
2. Senior Medical Talents Program of Chongqing for Young and Middle-aged
(2020GDRC005)” were erroneously omitted.

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.